Cargando…

Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways

BACKGROUND: Breast cancer (BC) is one of the most common malignant tumors with the highest mortality in the world. Modern pharmacological studies have shown that Syringin has an inhibitory effect on many tumors, but its anti-BC efficacy and mechanism are still unclear. METHODS: First, Syringin was i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fei, Yuan, Chong, Liu, Bo, Yang, Yan-Fang, Wu, He-Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258109/
https://www.ncbi.nlm.nih.gov/pubmed/35794555
http://dx.doi.org/10.1186/s12967-022-03504-6
_version_ 1784741469371760640
author Wang, Fei
Yuan, Chong
Liu, Bo
Yang, Yan-Fang
Wu, He-Zhen
author_facet Wang, Fei
Yuan, Chong
Liu, Bo
Yang, Yan-Fang
Wu, He-Zhen
author_sort Wang, Fei
collection PubMed
description BACKGROUND: Breast cancer (BC) is one of the most common malignant tumors with the highest mortality in the world. Modern pharmacological studies have shown that Syringin has an inhibitory effect on many tumors, but its anti-BC efficacy and mechanism are still unclear. METHODS: First, Syringin was isolated from Acanthopanax senticosus (Rupr. & Maxim.) Harms (ASH) by systematic solvent extraction and silica gel chromatography column. The plant name is composed of genus epithet, species additive words and the persons’ name who give its name. Then, the hub targets of Syringin against BC were revealed by bioinformatics. To provide a more experimental basis for later research, the hub genes which could be candidate biomarkers of BC and a ceRNA network related to them were obtained. And the potential mechanism of Syringin against BC was proved in vitro experiments. RESULTS: Syringin was obtained by liquid chromatography-mass spectrometry (LC–MS), nuclear magnetic resonance (NMR), and high-performance liquid chromatography (HPLC). Bioinformatics results showed that MAP2K1, PIK3CA, HRAS, EGFR, Caspase3, and PTGS2 were the hub targets of Syringin against BC. And PIK3CA and HRAS were related to the survival and prognosis of BC patients, the PIK3CA-hsa-mir-139-5p-LINC01278 and PIK3CA-hsa-mir-375 pathways might be closely related to the mechanism of Syringin against BC. In vitro experiments confirmed that Syringin inhibited the proliferation and migration and promoted apoptosis of BC cells through the above hub targets. CONCLUSIONS: Syringin against BC via PI3K-AKT-PTGS2 and EGFR-RAS-RAF-MEK-ERK pathways, and PIK3CA and HRAS are hub genes for adjuvant treatment of BC. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03504-6.
format Online
Article
Text
id pubmed-9258109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92581092022-07-07 Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways Wang, Fei Yuan, Chong Liu, Bo Yang, Yan-Fang Wu, He-Zhen J Transl Med Research BACKGROUND: Breast cancer (BC) is one of the most common malignant tumors with the highest mortality in the world. Modern pharmacological studies have shown that Syringin has an inhibitory effect on many tumors, but its anti-BC efficacy and mechanism are still unclear. METHODS: First, Syringin was isolated from Acanthopanax senticosus (Rupr. & Maxim.) Harms (ASH) by systematic solvent extraction and silica gel chromatography column. The plant name is composed of genus epithet, species additive words and the persons’ name who give its name. Then, the hub targets of Syringin against BC were revealed by bioinformatics. To provide a more experimental basis for later research, the hub genes which could be candidate biomarkers of BC and a ceRNA network related to them were obtained. And the potential mechanism of Syringin against BC was proved in vitro experiments. RESULTS: Syringin was obtained by liquid chromatography-mass spectrometry (LC–MS), nuclear magnetic resonance (NMR), and high-performance liquid chromatography (HPLC). Bioinformatics results showed that MAP2K1, PIK3CA, HRAS, EGFR, Caspase3, and PTGS2 were the hub targets of Syringin against BC. And PIK3CA and HRAS were related to the survival and prognosis of BC patients, the PIK3CA-hsa-mir-139-5p-LINC01278 and PIK3CA-hsa-mir-375 pathways might be closely related to the mechanism of Syringin against BC. In vitro experiments confirmed that Syringin inhibited the proliferation and migration and promoted apoptosis of BC cells through the above hub targets. CONCLUSIONS: Syringin against BC via PI3K-AKT-PTGS2 and EGFR-RAS-RAF-MEK-ERK pathways, and PIK3CA and HRAS are hub genes for adjuvant treatment of BC. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03504-6. BioMed Central 2022-07-06 /pmc/articles/PMC9258109/ /pubmed/35794555 http://dx.doi.org/10.1186/s12967-022-03504-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Fei
Yuan, Chong
Liu, Bo
Yang, Yan-Fang
Wu, He-Zhen
Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
title Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
title_full Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
title_fullStr Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
title_full_unstemmed Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
title_short Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
title_sort syringin exerts anti-breast cancer effects through pi3k-akt and egfr-ras-raf pathways
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258109/
https://www.ncbi.nlm.nih.gov/pubmed/35794555
http://dx.doi.org/10.1186/s12967-022-03504-6
work_keys_str_mv AT wangfei syringinexertsantibreastcancereffectsthroughpi3kaktandegfrrasrafpathways
AT yuanchong syringinexertsantibreastcancereffectsthroughpi3kaktandegfrrasrafpathways
AT liubo syringinexertsantibreastcancereffectsthroughpi3kaktandegfrrasrafpathways
AT yangyanfang syringinexertsantibreastcancereffectsthroughpi3kaktandegfrrasrafpathways
AT wuhezhen syringinexertsantibreastcancereffectsthroughpi3kaktandegfrrasrafpathways